Video: Exela's Domestic Pharmaceutical Manufacturing Facility in Action

Watch the video above to see Exela® Pharma Sciences’ facility in action, and how we’re protecting the future of the pharmaceutical supply chain together.

Together with our valued members and stakeholders across the supply chain, Premier has been a long-time leader in addressing supply chain challenges and drug shortages.

Recently, the Premier team, member health systems, and government and community leaders had the opportunity to see first-hand our innovative strategies in action.

The group visited  Exela® Pharma Sciences’ Lenoir, NC headquarters and state-of-the-art manufacturing facility that’s helping to support domestic production, prevent and alleviate drug shortages, and enhance supply chain resiliency for critical pharmaceuticals – while boosting economic development and creating jobs on U.S. soil.

Through an innovative model, Premier and our members’ investment in Exela (and other domestic producers) and provide up-front capital, aggregated demand and buying commitments vital for manufacturers to increase drug supply, invest in redundancies, enter or re-enter markets and explore new therapeutic categories for innovation.

The Exela investment:

• Gives providers access to 20+ high-quality, U.S.-made pharmaceutical products and safety stock.
• Includes several generic injectables that frequently appear on the U.S. Food and Drug Administration (FDA) drug shortage list, as well as 503B pharmaceutical products made by Exela.
• Gave Exela much-needed capital to  invest in domestic production and  drive innovations to bolster supply.
• Creates a partnership where providers have a seat at the table to share insights into the drugs needed most to care for patients.

The Exela initiative builds on Premier’s commitment to provide the industry with concrete solutions that help create healthier pharmaceutical markets and provide greater access to life-saving products.

• Since 2020, Premier programs have successfully resolved  15 drug shortages, resulting in their official delisting from the FDA shortage list at this time.
• We’ve also contracted with an additional 29 suppliers for generic injectables — suppliers that were not in the injectables market in 2012, adding much-needed competition to these therapeutic categories.
• Premier’s  own distribution channel dynamically allocates products based on clinical need, rather than by purchase history, as other distributors traditionally do.
• Leveraging artificial intelligence (AI) and machine learning to mine robust data, Premier provides early communication to both our members and government stakeholders on potential or impending product shortages.
• And Premier continues to offer Congress, the FDA and other government stakeholders policy recommendations and solutions to eliminate drug shortages.

With added diversity, domestic investments and capacity, greater supply chain visibility and a collaborative approach – we can take steps now to ensure greater preparedness, protect patients and healthcare workers and insulate us from drug shortages in the future.

Learn more about our investments in the domestic production of pharmaceuticals, face masks, gloves, gowns and incontinence products.